Shimadzu analyzed the blood concentration of anti-inflammatory drug infliximab*1 using mass spectrometry and nSMOL Antibody BA Kit. Infliximab is a therapeutic antibody that blocks a tumor necrosis factor (TNF-a) for the alleviation of systemic arthritis. While the development of infliximab has led to significant progress in the treatment of RA, it has not been sufficiently effective for some patients. Furthermore, clarifying clinical information for optimal infliximab level is expected to make a great clinical challenge in terms of both patients and the medical costs since several autoimmune diseases require long-term management for the treatment.
In this study, we used a database of Japanese RA patients (KURAMA cohort*2) to determine a cutoff value for infliximab treatment in practical treatment. And we showed that infliximab monitoring has the potential to identify a group of patients with decreased response during treatment and to provide criteria for optimal subsequent options. This study was conducted with the approval of the
'The usability of measuring the blood level of antibody drugs, including infliximab, has been clinically remarkable around the world. We expect that individualized treatment using mass spec-based antibody monitoring technology will contribute to more effective antibody therapy and the control of medical costs.' said
Since 2017, Shimadzu has been working with
*1 A therapeutic antibody that inhibits TNF-a signaling and is used for the treatment of many autoimmune diseases.
*2 Cohort study for the integrated RA research in
https://www.racenter.kuhp.kyoto-u.ac.jp/activity/running-study/kurama-study
For more information, please refer to the following original paper published in PLOS ONE of
Potential application of measuring serum infliximab levels in rheumatoid arthritis management: A retrospective study based on KURAMA cohort data
Nakae K, Masui S, Yonezawa A, Hashimoto M, Watanabe R, Murata K, Murakami K, Tanaka M, Ito H, Yokoyama K, Iwamoto N, Shimada T, Nakamura M, Denda M, Itohara K, Nakagawa S, Ikemi Y, Imai S, Nakagawa T, Hayakari M, Matsubara K
See more at: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0258601
(C) 2021 Electronic News Publishing, source